NCT02287311 2026-03-23
MABEL
Baylor College of Medicine
Phase 1 Active not recruiting
Clinical Trials
21 trialsNCT03267498 2026-01-12
Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
University of California, San Francisco
Phase 2 Completed
NCT04458909 2025-10-03
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT05166577 2025-03-12
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Viracta Therapeutics, Inc.
Phase 1 Terminated
NCT02538510 2024-11-26
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
University of Washington
Phase 1/2 Completed
NCT03474640 2024-11-22
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Completed
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT03558191 2024-03-15
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03682055 2023-08-15
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
Phase 1/2 Terminated
NCT00834093 2023-06-28
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02578641 2023-06-28
VANCE
Tessa Therapeutics
Phase 3 Completed
NCT02605967 2022-02-10
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Novartis
Phase 2 Completed
NCT00592501 2021-10-26
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT01344356 2020-04-10
Stereotactic Body Radiotherapy for Head and Neck Tumors
Mercy Research
Phase 4 Completed
NCT02339558 2019-09-13
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01621880 2019-01-09
BRAIN
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT02269943 2018-12-12
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
Phase 2 Completed
NCT02584790 2017-12-08
NBI to Detect Post-RT Mucosal Residual NPC
Pamela Youde Nethersole Eastern Hospital
Phase NA Completed
NCT00565448 2015-07-30
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
Sanofi
Phase 2 Completed
NCT00815087 2014-03-26
Functional Electrical Stimulation in Irradiated Nasopharyngeal Carcinoma (NPC)
National Taiwan University Hospital
Phase 2 Completed
NCT00700440 2010-03-26
ENCORE
Sun Yat-sen University
Phase 2 Completed